Last reviewed · How we verify
NCT07398638
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
Phase 1, PHASE2 trial testing R-CHOP in Diffuse Large B Cell Lymphoma (DLBCL) in 122 participants. Not yet recruiting.
28 February 2029
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 122 |
| Start date | 28 February 2026 |
| Primary completion | 28 February 2029 |
| Estimated completion | 28 February 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- R-CHOP — full drug profile →
- POLA-R-CHP — full drug profile →
- Lisaftoclax — full drug profile →
Conditions studied
- Diffuse Large B Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B Cell Lymphoma (DLBCL) →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 70, any sex, with Diffuse Large B Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter, open-label Phase Ib/II clinical study designed to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of lisatoclax in combination with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07398638
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of R-CHOP
Trials testing the same drug.
- NCT07494565 — Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL · Phase 2 · not yet recruiting
- NCT06890585 — Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor · Phase 2 · not yet recruiting
- NCT06549595 — A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients · Phase 3 · recruiting
- NCT07348575 — A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment · Phase 3 · enrolling by invitation
- NCT05051891 — A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide · Phase 3 · completed
Other recruiting trials for Diffuse Large B Cell Lymphoma (DLBCL)
Currently open trials in the same condition.
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
- NCT07371923 — Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma · Phase 2 · recruiting
- NCT07062627 — Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma · Phase 2 · recruiting
- NCT07260812 — KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 1 · recruiting
- NCT07124936 — A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07398638 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07398638.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing